Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6137-6149

  Ren, Wuze ^a   Mumbauer, Alexandra ^a   Gettie, Agegnehu ^a   Seaman, Michael S ^b   Russell Lodrigue, Kasi ^c   Blanchard, James ^c   Westmoreland, Susan ^d   Cheng Mayer, Cecilia ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; NEUTRALIZING ANTIBODY; SOLUBLE CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; GIANT CELL ENCEPHALITIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; LAMINA PROPRIA; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RHESUS MONKEY; SEROCONVERSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL TROPISM; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; RECEPTORS, HIV; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84878165866     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00178-13     Document Type: Article

References (81)

1. Hemelaar J. 2012. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 18:182-192.
2. Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, Lo YR, Mellors JW, O'Reilly K, Paxton L, Roffenbender JS, Warren M, Piot P, Dybul MR. 2010. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J. Int. AIDS Soc. 13:24. doi: 10.1186/1758-2652-13-24.
3. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. 2010. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr. HIV/AIDS Rep. 7:210 -219.
4. Cohen MS, Baden LR. 2012. Preexposure prophylaxis for HIV-where do we go from here? N. Engl. J. Med. 367:459-461.
5. De Cock KM, Crowley SP, Lo YR, Granich RM, Williams BG. 2009. Preventing HIV transmission with antiretrovirals. Bull. World Health Organ. 87:488-488A.
6. Gostin LO, Kim SC. 2011. Ethical allocation of preexposure HIV prophylaxis. JAMA 305:191-192.
7. Global HIV/AIDS Vaccine Enterprise. 2005. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med. 2:e25. doi:10.1371 /journal.pmed.0020025.
8. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, Haynes BF, Baltimore D, Collins C, Douglas RG, Esparza J, Francis DP, Ganguly NK, Gerberding JL, Johnston MI, Kazatchkine MD, McMichael AJ, Makgoba MW, Pantaleo G, Piot P, Shao Y, Tramont E, Varmus H, Wasserheit JN. 2003. Medicine. The need for a global HIV vaccine enterprise. Science 300:2036 -2039.
9. Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L. 2008. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5:e173. doi:10.1371/journal.pmed.0050173.
10. Etemad-Moghadam B, Karlsson GB, Halloran M, Sun Y, Schenten D, Fernandes M, Letvin NL, Sodroski J. 1998. Characterization of simianhuman immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J. Virol. 72:8437- 8445.
11. Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L. 2007. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 81:6402- 6411.
12. Miyazaki Y, Kuwata T, Takehisa J, Hayami M. 2002. Analysis of a primary isolate-like virus from simian and human immunodeficiency virus- infected macaque having broad neutralizing activity. AIDS Res. Hum. Retroviruses 18:469-475.
13. Montefiori DC, Reimann KA, Wyand MS, Manson K, Lewis MG, Collman RG, Sodroski JG, Bolognesi DP, Letvin NL. 1998. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J. Virol. 72:3427-3431.
14. Malenbaum SE, Yang D, Cheng-Mayer C. 2001. Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques. J. Virol. 75:9287-9296.
15. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162- derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80:8745- 8762.
16. Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, Zolla-Pazner S, Gorny MK, Kraft Z, Stamatatos L. 2010. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J. Virol. 84:3443-3453.
17. Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, Shingai M, Pejchal R, Ramos A, Simek MD, Geng Y, Wilson IA, Poignard P, Martin MA, Burton DR. 2011. Rapid development of glycan- specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. U. S. A. 108:20125-20129.
18. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
19. Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, Morgan D, Beddows S, Weber J, Whitworth JA. 2007. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J. Acquir. Immune Defic. Syndr. 45:28 -33.
20. Schuitemaker H, van 't Wout AB, Lusso P. 2011. Clinical significance of HIV-1 coreceptor usage. J. Transl. Med. 9(Suppl. 1):S5. doi:10.1186/1479 -5876-9-S1-S5.
21. Patel MB, Hoffman NG, Swanstrom R. 2008. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 82:903-916.
22. Coetzer M, Cilliers T, Ping LH, Swanstrom R, Morris L. 2006. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 356:95-105.
23. Raymond S, Delobel P, Mavigner M, Ferradini L, Cazabat M, Souyris C, Sandres-Saune K, Pasquier C, Marchou B, Massip P, Izopet J. 2010. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J. Acquir. Immune Defic. Syndr. 53:167-175.
24. Cayabyab M, Rohne D, Pollakis G, Mische C, Messele T, Abebe A, Etemad-Moghadam B, Yang P, Henson S, Axthelm M, Goudsmit J, Letvin NL, Sodroski J. 2004. Rapid CD4 T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian clade C HIV type 1 isolate. AIDS Res. Hum. Retroviruses 20:27- 40.
25. Chen Z, Huang Y, Zhao X, Skulsky E, Lin D, Ip J, Gettie A, Ho DD. 2000. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). J. Virol. 74:6501- 6510.
26. Ndung'u T, Lu Y, Renjifo B, Touzjian N, Kushner N, Pena-Cruz V, Novitsky VA, Lee TH, Essex M. 2001. Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model. J. Virol. 75:11417-11425.
27. Wu Y, Hong K, Chenine AL, Whitney JB, Xu W, Chen Q, Geng Y, Ruprecht RM, Shao Y. 2005. Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate. J. Med. Primatol. 34:101-107.
28. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, Grisson RD, Wood C, Zhang H, Kankasa C, Amara RR, Else JG, Novembre FJ, Montefiori DC, Ruprecht RM. 2009. Neutralization- sensitive R5-tropic simian-human immunodeficiency virus SHIV-
29. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, Li PL, Shai-Kobiler E, Wang T, McCann CM, Zhang H, Wood C, Kankasa C, Secor WE, McClure HM, Strobert E, Else JG, Ruprecht RM. 2006. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J. Virol. 80:8729-8738.
30. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, Chenine AL, Kramer VG, Siddappa NB, Xu W, Else JG, Novembre FJ, Strobert E, O'Neil SP, Ruprecht RM. 2008. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 5:94. doi:10.1186/1742-4690-5-94.
31. Ho SH, Tasca S, Shek L, Li A, Gettie A, Blanchard J, Boden D, Cheng-Mayer C. 2007. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J. Virol. 81:8621- 8633.
32. Ren W, Tasca S, Zhuang K, Gettie A, Blanchard J, Cheng-Mayer C. 2010. Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection. J. Virol. 84:340 -351.
33. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. 2004. Envelope-constrained neutralization- sensitive HIV-1 after heterosexual transmission. Science 303:2019- 2022.
34. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776 -11790.
35. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896 -1905.
36. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
37. Goulder PJ, Watkins DI. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol
38. Delwart EL, Gordon CJ. 1997. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 12:348 -354.
39. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. Bioinformatics (Oxford, Engl.) 23:2947-2948.
40. Ho SH, Shek L, Gettie A, Blanchard J, Cheng-Mayer C. 2005. V3 loop-determined coreceptor preference dictates the dynamics of CD4- T-cell loss in simian-human immunodeficiency virus-infected macaques. J. Virol. 79:12296 -12303.
41. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O'Connor DH, Carrington M, Watkins DI. 2006. The highfrequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80:5074 -5077.
42. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. 1999. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5:535-541.
43. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, Baskin G, Cheng-Mayer C. 2001. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIVSF162P3. J. Virol. 75:1990 -1995.
44. Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H. 1998. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177:600-610.
45. Shakirzyanova M, Tsai L, Ren W, Gettie A, Blanchard J, Cheng-Mayer C. 2012. Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J. Virol. 86:9432- 9442.
46. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
47. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, Williamson C, Morris L, CAPRISA 002 Study Team. 2008. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82: 1860-1869.
48. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594. doi:10.1371/journal.ppat.1000594.
49. Buch S, Pinson D, Hou Y, Adany I, Li Z, Mukherjee S, Jia F, Mackay G, Silverstein P, Kumar A, Narayan O. 2000. Neuropathogenesis of chimeric simian human immunodeficiency virus infection in rhesus macaques. J. Med. Primatol. 29:96 -106.
50. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. 1988. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239:586 -592.
51. Lackner AA, Dandekar S, Gardner MB. 1991. Neurobiology of simian and feline immunodeficiency virus infections. Brain Pathol. 1:201-212.
52. Raghavan R, Stephens EB, Joag SV, Adany I, Pinson DM, Li Z, Jia F, Sahni M, Wang C, Leung K, Foresman L, Narayan O. 1997. Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus macaques. Brain Pathol. 7:851- 861.
53. Miller CJ, Genesca M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. 2007. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J. Virol. 81:5024 -5035.
54. Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, Khunkhun R, Piatak M, Lifson JD, Grosschupff G, Gelman RS, Racz P, Tenner-Racz K, Mansfield KA, Letvin NL, Montefiori DC, Reimann KA. 2003. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77:2165-2173.
55. Huang KH, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, Main J, Muir D, Weber JN, Frater AJ, Phillips RE, Pybus OG, Goulder PJ, McClure MO, Cooke GS, Klenerman P. 2010. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat. Commun. 1:102. doi:10.1038/ncomms1100.
56. Kolchinsky P, Kiprilov E, Sodroski J. 2001. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75:2041-2050.
57. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. 2001. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75:3435-3443.
58. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82:638- 651.
59. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76:7306 -7321.
60. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neu-tralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
61. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028. doi:10.1371 /journal.ppat.1001028.
62. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L, CAPRISA 002 Study Team. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
63. Gray ES, Moore PL, Pantophlet RA, Morris L. 2007. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 81: 10769-10776.
64. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. 2012. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18:1688 -1692.
65. Jensen MA, Coetzer M, van 't Wout AB, Morris L, Mullins JI. 2006. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J. Virol. 80:4698-4704.
66. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76:8953- 8957.
67. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949- 1953.
68. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025- 1028.
69. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, Sodroski J. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557- 4565.
70. Yang ZY, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, Panet A, Mascola JR, Nabel GJ. 2004. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J. Virol. 78:4029-4036.
71. Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW. 2007. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 3:e117. doi:10.1371/journal.ppat.0030117.
72. Shakirzyanova M, Ren W, Zhuang K, Tasca S, Cheng-Mayer C. 2010. Fitness disadvantage of transitional intermediates contributes to dynamic change in the infecting-virus population during coreceptor switch in R5 simian/human immunodeficiency virus-infected macaques. J. Virol. 84: 12862-12871.
73. Almond D, Krachmarov C, Swetnam J, Zolla-Pazner S, Cardozo T. 2012. Resistance of subtype C HIV-1 strains to anti-V3 loop antibodies. Adv. Virol. 2012:803535.
74. Zhuang K, Finzi A, Tasca S, Shakirzyanova M, Knight H, Westmoreland S, Sodroski J, Cheng-Mayer C. 2011. Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One 6:e21350. doi:10.1371/journal.pone.0021350.
75. Kolson DL, Gonzalez-Scarano F. 2000. HIV and HIV dementia. J. Clin. Invest. 106:11-13.
76. Clifford DB, Mitike MT, Mekonnen Y, Zhang J, Zenebe G, Melaku Z, Zewde A, Gessesse N, Wolday D, Messele T, Teshome M, Evans S. 2007. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J. Neurovirol. 13:67-72.
77. Riedel D, Ghate M, Nene M, Paranjape R, Mehendale S, Bollinger R, Sacktor N, McArthur J, Nath A. 2006. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India. J. Neurovirol. 12:34 -38.
78. Robertson K, Kopnisky K, Hakim J, Merry C, Nakasujja N, Hall C, Traore M, Sacktor N, Clifford D, Newton C, Van Rie A, Holding P, Clements J, Zink C, Mielk J, Hosseinipour M, Lalloo U, Amod F, Marra C, Evans S, Liner J, Second Assessment of NeuroAIDS in Africa Conference Participants. 2008. Second assessment of neuroAIDS in Africa. J. Neurovirol. 14:87-101.
79. Mahadevan A, Shankar SK, Satishchandra P, Ranga U, Chickabasaviah YT, Santosh V, Vasanthapuram R, Pardo CA, Nath A, Zink MC. 2007. Characterization of human immunodeficiency virus (HIV)-infected cells in infiltrates associated with CNS opportunistic infections in patients with HIV clade C infection. J. Neuropathol. Exp. Neurol. 66:799-808.
80. Humes D, Overbaugh J. 2011. Adaptation of subtype A human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. J. Virol. 85:4409-4420.
81. Humes D, Emery S, Laws E, Overbaugh J. 2012. A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J. Virol. 86:12472-12483.